Previous 10 | Next 10 |
2023-03-08 08:38:01 ET Opko Health's ( NASDAQ: OPK ) ModeX Therapeutics signed a worldwide license agreement with Merck ( NYSE: MRK ) to develop its preclinical Epstein-Barr Virus (EBV) vaccine candidate MDX-2201. EBV, also known as human herpesvirus 4, is a m...
2023-03-08 08:36:27 ET Fresh Tracks Therapeutics ( FRTX ) +83% on announcing positive topline results from single and multiple ascending dose parts of phase 1 study of Oral DYRK1A Inhibitor FRTX-02. Kimball International ( KBAL ) +75% HNI to acquire Kimball i...
MDX-2201 leverages ModeX’s innovative biologics platform to target multiple Epstein-Barr virus (EBV) proteins EBV is the leading cause of infectious mononucleosis and is also associated with some specific types of cancer MIAMI, March 08, 2023 (GLOBE NEWSWIRE) -- OPKO Health...
Summary Losses continue to mount and revenue falls from diagnostics paint an unhealthy investment picture for retail value investors. One drug generates the primary revenue while management attempts to turn a profit mostly from diagnostics through deep cost-cutting and site closures. ...
Image source: The Motley Fool. Opko Health (NASDAQ: OPK) Q4 2022 Earnings Call Feb 23, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: Opko Health (OPK) Q4 2022 Earnings Call Transcript
OPKO Health, Inc. (OPK) Q4 2022 Earnings Conference Call February 23, 2023, 16:30 ET Company Participants Yvonne Briggs - LHA Investor Relations Phillip Frost - Chairman & CEO Elias Zerhouni - President & Vice Chairman Steven Rubin - EVP, Administration &am...
OPKO Health press release ( NASDAQ: OPK ): Q4 GAAP EPS of -$0.11 in-line. Revenue of $185.4M (-53.8% Y/Y) beats by $17.19M . Pharmaceuticals: Revenue from products in the fourth quarter of 2022 increased to $37.9 million from $35.3 million in the fourth quarter of 2021, dr...
MIAMI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, 2022. Business highlights include the following: Sales are underway by Pfizer for NGENLA® (somatrogon) in 15 co...
MIAMI, Feb. 16, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2022 after the close of the U.S. financial markets on Thursday, February 23, 2023. OPKO’s senior management will provide a bu...
BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings PR Newswire CINtec ® PLUS Cytology offered as a reflex test when cytology is NILM and HPV positive ELMWOOD PARK, N.J. , Feb. 9, 2023 /P...
News, Short Squeeze, Breakout and More Instantly...
MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized the repurchase of up to $100 million of shares of the Company's common stock. Under the repurchase program, OPKO may repurchase shares of its common ...
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPKO’s profit share payments from Pfizer received pursuant to its license agreement relat...
NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner PR Newswire New Marketing Partner to Support the Expanded Sales of OPKO-Branded Products Throughout China on Additi...